Phase 2 study of PDS0101 in combination with KEYTRUDA (pembrolizumab) in patients with recurrent or metastatic head and neck cancer and high-risk human papillomavirus-16 (HPV16) infection after failure with platinum-based chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 12 Jul 2017
At a glance
- Drugs PDS 0101 (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer; Human papillomavirus infections
- Focus Therapeutic Use
- 12 Jul 2017 New trial record